Search Results

Cancer Equity From Patient Advocates Financial toxicity, lack of information dissemination, and historical instances of medical mistrust threaten underserved communities’ ability and willingness to participate in cancer prevention, routine cancer

just how widespread the current platinum chemotherapy shortage is, and shared a statement calling on the whole oncology community to work together on solutions. “This is an unacceptable situation. We are hearing from oncologists and pharmacists

advocate of health services research, was deeply concerned about discordant patterns of cancer care in both academic and community cancer centers in the face of compelling evidence from clinical trials. Dr. Winn felt strongly that the best strategy for

of all kinds because one of the provisions in the draft proposal was to redirect patients to community hospitals, which were far less expensive than academic hospitals. I had been at Memorial Sloan Kettering Cancer Center for only a year and became

enrollment . J Clin Oncol 2001 ; 19 : 1728 – 1733 . 12 Winn RJ . Obstacles to the accrual of patients to clinical trials in the community setting . Semin Oncol 1994 ; 21 ( Suppl 7 ): 112 – 117 . 13 Comis RLl Miller JD Aldige CR

health plans and health insurance companies should be looking for value for their premium dollars, not only lower costs. Most cancer care can be obtained in the community, but an estimated 10% to 15% of cancer patients should have the option of treatment

: results from a prospective community oncology study . J Clin Oncol 1998 ; 16 : 3412 – 3425 . 5 Glaus A Crow R Hammond S . A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals

conduct of clinical trials. We can further challenge ourselves as a comprehensive cancer care community by asking “How do I expand prognostic modeling within my own work?” Some thoughts on this are below: Existing knowledge: What are the prognostic

NHW formed the majority in this group (p<0.001). NHW formed over half of accrued pts in every Rx center (86% comprehensive community cancer, 78% academic, 75% community cancer, and 72% integrated network cancer center). Of the non-White pts, majority

receive monoclonal antibodies for protection.” NCCN’s recommendations point out that vaccine hesitancy in the general population impedes the development of herd (community) immunity, which leaves people with cancer at higher risk. Reducing community